Abstract:Hepatic physiology depends on the liver's complex structural composition which among others, provides high oxygen supply rates, locally differential oxygen tension, endothelial paracrine signaling, as well as residual hemodynamic shear stress to resident hepatocytes. While functional improvements were shown by implementing these factors into hepatic culture systems, direct cause‐effect relationships are often not well characterized—obfuscating their individual contribution in more complex microphysiological systems. By comparing increasingly complex hepatic in vitro culture systems that gradually implement these parameters, we investigate the influence of the cellular microenvironment to overall hepatic functionality in pharmacological applications. Here, hepatocytes were modulated in terms of oxygen tension and supplementation, endothelial coculture, and exposure to fluid shear stress delineated from oxygen influx. Results from transcriptomic and metabolomic evaluation indicate that particularly oxygen supply rates are critical to enhance cellular functionality—with cellular drug metabolism remaining comparable to physiological conditions after prolonged static culture. Endothelial signaling was found to be a major contributor to differential phenotype formation known as metabolic zonation, indicated by WNT pathway activity. Lastly, oxygen‐delineated shear stress was identified to direct cellular fate towards increased hepatic plasticity and regenerative phenotypes at the cost of drug metabolic functionality – in line with regenerative effects observed in vivo. With these results, we provide a systematic evaluation of critical parameters and their impact in hepatic systems. Given their adherence to physiological effects in vivo, this highlights the importance of their implementation in biomimetic devices, such as organ‐on‐a‐chip systems. Considering recent advances in basic liver biology, direct translation of physiological structures into in vitro models is a promising strategy to expand the capabilities of pharmacological models.

Organoid-guided Precision Hepatology for Metabolic Liver Disease

Insight to Biofabrication of Liver Microtissues for Disease Modeling: Challenges and Opportunities

Single-cell transcriptomics stratifies organoid models of metabolic dysfunction-associated steatotic liver disease

Customized liver organoids as an advanced in vitro modeling and drug discovery platform for non-alcoholic fatty liver diseases

Human Liver Organoid: Modeling Liver Steatosis and Beyond

Human Hepatobiliary Organoids: Recent Advances in Drug Toxicity Verification and Drug Screening

Patient-derived organoid models to decode liver pathophysiology

Three-Dimensional Organoids as a Model to Study Nonalcoholic Fatty Liver Disease

Modeling drug-induced liver injury and screening for anti-hepatofibrotic compounds using human PSC-derived organoids

Generation of Fibrotic Liver Organoids Using Hepatocytes, Primary Liver Sinusoidal Endothelial Cells, Hepatic Stellate Cells, and Macrophages

Liver Organoids: Established Tools for Disease Modeling and Drug Development

Protocol to generate human liver spheroids to study liver fibrosis induced by metabolic stress

The liver organoid's past, present and future: a personalized medicine strategy

Using Liver Organoids as Models to Study the Pathobiology of Rare Liver Diseases

Human liver organoids: From generation to applications

A multicellular liver organoid model for investigating hepatitis C virus infection and nonalcoholic fatty liver disease progression

Mechanobiological stimulation in organ‐on‐a‐chip systems reduces hepatic drug metabolic capacity in favor of regenerative specialization

Generation of Human Fatty Livers Using Custom-Engineered Induced Pluripotent Stem Cells with Modifiable SIRT1 Metabolism.

Liver organoids: updates on generation strategies and biomedical applications

Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis